Sorry, you need to enable JavaScript to visit this website.

Relapsed: D+VD Study | DARZALEX® IV (daratumumab)

DARZALEX® Clinical Studies:

DARZALEX® in combination with Velcade®
(bortezomib) + dexamethasone

DARZALEX® was studied in combination with Velcade® and dexamethasone (Vd) vs Vd alone in 498 patients who had received at least one prior medicine to treat their multiple myeloma.

The main goal of the study was to measure the length of time patients lived without their multiple myeloma getting worse.

Another goal was to measure overall response rate, which is the percentage of patients who responded to treatment.

Clinical study results: DARZALEX® + Vd vs Vd alone

DARZALEX® in combination with Vd increased the time patients lived without their multiple myeloma getting worse.

73percent

of patients lived without their disease getting worse
with DARZALEX® + Vd (n=251) vs 51% of patients
treated with Vd alone (n=247).*

*At a median follow-up of 7.4 months.

More patients responded to DARZALEX® in combination with Vd vs Vd alone

8outof10

79% of patients responded to DARZALEX® + Velcade® + dexamethasone (DVd) (n=251) vs 60% of patients treated with Vd alone (n=247).

Learn how this DARZALEX® treatment regimen is given